

Yong Sang Song

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2249644/publications.pdf>

Version: 2024-02-01

115
papers

3,878
citations

87888

38
h-index

149698

56
g-index

116
all docs

116
docs citations

116
times ranked

5984
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy. <i>Cancer Research and Treatment</i> , 2022, 54, 1219-1229.	3.0	1
2	Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells. <i>Cell Death and Disease</i> , 2022, 13, 169.	6.3	8
3	Wnt/ β -Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	4
4	Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer. <i>Cancer Letters</i> , 2022, 542, 215735.	7.2	27
5	A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2021, 124, 375-382.	6.4	6
6	Piceatannol Is Superior to Resveratrol at Suppressing Adipogenesis in Human Visceral Adipose-Derived Stem Cells. <i>Plants</i> , 2021, 10, 366.	3.5	7
7	Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer. <i>Molecular Carcinogenesis</i> , 2021, 60, 297-312.	2.7	15
8	Laterally Extended Endopelvic Resection Versus Chemo or Targeted Therapy Alone for Pelvic Sidewall Recurrence of Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 683441.	2.8	2
9	Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy. <i>Biomolecules</i> , 2021, 11, 1107.	4.0	21
10	Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique. <i>Gynecologic Oncology</i> , 2021, 162, 72-79.	1.4	10
11	Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemosensitivity and Glycolytic Regulation in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3399.	3.7	5
12	GNAI2/gip2-Regulated Transcriptome and Its Therapeutic Significance in Ovarian Cancer. <i>Biomolecules</i> , 2021, 11, 1211.	4.0	8
13	Unraveling Autocrine Signaling Pathways through Metabolic Fingerprinting in Serous Ovarian Cancer Cells. <i>Biomedicines</i> , 2021, 9, 1927.	3.2	7
14	Decursin and Decursinol Angelate Suppress Adipogenesis through Activation of β -catenin Signaling Pathway in Human Visceral Adipose-Derived Stem Cells. <i>Nutrients</i> , 2020, 12, 13.	4.1	11
15	ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer. <i>Antioxidants</i> , 2020, 9, 1137.	5.1	14
16	Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management. <i>Sports Medicine and Health Science</i> , 2020, 2, 202-210.	2.0	5
17	Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells. <i>Heliyon</i> , 2020, 6, e05442.	3.2	15
18	Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells. <i>Journal of Traditional and Complementary Medicine</i> , 2020, 10, 207-216.	2.7	13

#	ARTICLE	IF	CITATIONS
19	Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2020, 13, 67.	17.0	41
20	Sulforaphene Suppresses Adipocyte Differentiation via Induction of Post-Translational Degradation of CCAAT/Enhancer Binding Protein Beta (C/EBP β). <i>Nutrients</i> , 2020, 12, 758.	4.1	15
21	Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma. <i>Cancers</i> , 2020, 12, 559.	3.7	28
22	Plasma Gelsolin Inhibits CD8+ T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in Ovarian Cancer. <i>Cancer Research</i> , 2020, 80, 3959-3971.	0.9	28
23	Targeting cancer stem cells with phytochemicals for cancer therapy. , 2020, , 329-357.		0
24	Destabilization of TRAF6 by DRAK1 Suppresses Tumor Growth and Metastasis in Cervical Cancer Cells. <i>Cancer Research</i> , 2020, 80, 2537-2549.	0.9	15
25	Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets. <i>Journal of Cancer Prevention</i> , 2020, 25, 136-151.	2.0	27
26	Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. <i>Oncogene</i> , 2019, 38, 7089-7105.	5.9	116
27	Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer. <i>In Vivo</i> , 2019, 33, 863-868.	1.3	15
28	Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 925.	4.1	68
29	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. <i>Cancer Letters</i> , 2019, 442, 464-474.	7.2	70
30	Molecular and Cellular Basis of Chemoresistance in Ovarian Cancer. , 2019, , 575-593.		2
31	Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1144-1155.	3.0	17
32	Tumour microenvironment on mitochondrial dynamics and chemoresistance in cancer. <i>Free Radical Research</i> , 2018, 52, 1271-1287.	3.3	24
33	LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. <i>Cancer Research</i> , 2018, 78, 1923-1934.	0.9	61
34	Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer. <i>European Radiology</i> , 2018, 28, 2107-2114.	4.5	5
35	Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF- κ B activation. <i>Molecular Carcinogenesis</i> , 2018, 57, 235-242.	2.7	67
36	Activation of LXRE β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 1232.	2.6	38

#	ARTICLE	IF	CITATIONS
37	Tumor evolution and chemoresistance in ovarian cancer. <i>Npj Precision Oncology</i> , 2018, 2, 20.	5.4	106
38	Evaluating Tumor Evolution via Genomic Profiling of Individual Tumor Spheroids in a Malignant Ascites. <i>Scientific Reports</i> , 2018, 8, 12724.	3.3	17
39	Cyclooxygenase. , 2018, , 1275-1282.		0
40	Metformin induces degradation of cyclin D1 via AMPK/GSK3 β axis in ovarian cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 349-358.	2.7	51
41	Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer. <i>European Radiology</i> , 2017, 27, 16-23.	4.5	44
42	Prediction of Recurrence by Preoperative Intratumoral FDG Uptake Heterogeneity in Endometrioid Endometrial Cancer. <i>Translational Oncology</i> , 2017, 10, 178-183.	3.7	13
43	Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer. <i>European Radiology</i> , 2017, 27, 4510-4515.	4.5	8
44	Favorable factors for preserving bladder function after nerve-sparing radical hysterectomy: A protocol-based validation study. <i>Journal of Surgical Oncology</i> , 2017, 116, 492-499.	1.7	5
45	PGC1 α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 60299-60311.	1.8	54
46	Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway. <i>Cancer Research and Treatment</i> , 2017, 49, 338-349.	3.0	40
47	Prognostic factors in neuroendocrine cervical carcinoma. <i>Obstetrics and Gynecology Science</i> , 2016, 59, 116.	1.6	22
48	Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. <i>Oncotarget</i> , 2016, 7, 72845-72859.	1.8	13
49	Mitochondrial dynamics altered by oxidative stress in cancer. <i>Free Radical Research</i> , 2016, 50, 1065-1070.	3.3	62
50	Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. <i>Cancer Science</i> , 2016, 107, 1173-1178.	3.9	125
51	Gene expression profiles of human subcutaneous and visceral adipose-derived stem cells. <i>Cell Biochemistry and Function</i> , 2016, 34, 563-571.	2.9	29
52	Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 918-928.	2.7	88
53	Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2 α) pathway protect ovarian cancer cells from metformin-induced apoptosis. <i>Molecular Carcinogenesis</i> , 2016, 55, 346-356.	2.7	40
54	Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum Ca ²⁺ ATPase activity in ovarian cancer cells. <i>Cancer Letters</i> , 2016, 371, 30-37.	7.2	107

#	ARTICLE	IF	CITATIONS
55	Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. <i>Cancer Letters</i> , 2016, 371, 347-353.	7.2	70
56	Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R <i>in vitro</i> . <i>Oncotarget</i> , 2016, 7, 83148-83159.	1.8	37
57	Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Gl α 2, Src, and HIF1 α signaling nexus. <i>Oncotarget</i> , 2016, 7, 37664-37679.	1.8	44
58	Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 250-258.	3.0	52
59	Cyclooxygenase. , 2016, , 1-8.		0
60	The second annual conference of International ovarian cancer consortium and the symposium on tumor microenvironment and therapeutic resistance. <i>Genes and Cancer</i> , 2016, 7, 7-12.	1.9	0
61	Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. <i>Molecular Carcinogenesis</i> , 2015, 54, 1529-1540.	2.7	67
62	Conventional versus nerve-sparing radical surgery for cervical cancer: a meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 100.	2.2	38
63	ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis. <i>Frontiers in Oncology</i> , 2015, 5, 167.	2.8	60
64	Culture of preantral follicles in poly(ethylene) glycol-based, three-dimensional hydrogel: a relationship between swelling ratio and follicular developments. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2015, 9, 319-323.	2.7	19
65	Success Factors of Laparoscopic Nerve-sparing Radical Hysterectomy for Preserving Bladder Function in Patients with Cervical Cancer: A Protocol-Based Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 1987-1995.	1.5	21
66	Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	37
67	Stress Response, Inflammaging, and Cancer. , 2014, , 49-53.		3
68	Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. <i>Clinical and Experimental Medicine</i> , 2014, 14, 345-353.	3.6	79
69	Genotypic prevalence of human papillomavirus infection during normal pregnancy: A cross-sectional study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 200-207.	1.3	13
70	Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication. <i>Biochemical Pharmacology</i> , 2014, 92, 43-54.	4.4	50
71	Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 674-681.	6.4	23
72	Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1793-1799.	6.4	13

#	ARTICLE	IF	CITATIONS
73	Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 130, 446-451.	1.4	37
74	A feeder-free, defined three-dimensional polyethylene glycol-based extracellular matrix niche for culture of human embryonic stem cells. <i>Biomaterials</i> , 2013, 34, 3571-3580.	11.4	38
75	Cyclooxygenase-1 and -2: Molecular Targets for Cervical Neoplasia. <i>Journal of Cancer Prevention</i> , 2013, 18, 123-134.	2.0	31
76	Epigenetic Therapies as a Promising Strategy for Overcoming Chemoresistance in Epithelial Ovarian Cancer. <i>Journal of Cancer Prevention</i> , 2013, 18, 227-234.	2.0	18
77	Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis. <i>Cancer Research and Treatment</i> , 2013, 45, 193-201.	3.0	32
78	Paradoxical expression of <i>AHCYL1</i> affecting ovarian carcinogenesis between chickens and women. <i>Experimental Biology and Medicine</i> , 2012, 237, 758-767.	2.4	28
79	Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 162, 206-210.	1.1	34
80	Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. <i>Annals of the New York Academy of Sciences</i> , 2012, 1271, 20-32.	3.8	119
81	Body mass index and survival in patients with epithelial ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2012, 38, 70-76.	1.3	23
82	Safe Criteria for Less Radical Trachelectomy in Patients with Early-Stage Cervical Cancer: A Multicenter Clinicopathologic Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 1973-1979.	1.5	17
83	Metabolic approaches to overcoming chemoresistance in ovarian cancer. <i>Annals of the New York Academy of Sciences</i> , 2011, 1229, 53-60.	3.8	46
84	Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgery. <i>Gynecologic Oncology</i> , 2011, 121, 551-557.	1.4	24
85	Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. <i>Genes and Nutrition</i> , 2011, 6, 109-115.	2.5	50
86	Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer. <i>Gynecologic Oncology</i> , 2010, 119, 217-224.	1.4	41
87	Comparison of the efficacy between topotecan and belotecan, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: A single institutional experience. <i>Journal of Obstetrics and Gynaecology Research</i> , 2010, 36, 86-93.	1.3	12
88	Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 168-174.	2.8	43
89	Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study. <i>Gynecologic Oncology</i> , 2009, 113, 264-269.	1.4	92
90	Phase I/IIa Study of Combination Chemotherapy with CKD602 and Cisplatin in Patients with Recurrent Epithelial Ovarian Cancer. <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, 627-634.	3.8	10

#	ARTICLE	IF	CITATIONS
91	Matched-Case Comparison for the Role of Surgery in FIGO Stage Ib1â€“IIa Squamous Cell Carcinoma of Cervix and Suspicious Para-Aortic Lymph Node Metastasis. <i>Annals of Surgical Oncology</i> , 2009, 16, 133-9.	1.5	4
92	Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 109, 359-363.	1.4	19
93	Human Papillomavirus Infection and Cervical Cancer Prevention in Japan and Korea. <i>Vaccine</i> , 2008, 26, M30-M42.	3.8	48
94	Increasing trend in the incidence of cervical cancer among the elderly in Korea: A population-based study from 1993 to 2002. <i>Acta OncolÃ³gica</i> , 2007, 46, 852-858.	1.8	5
95	The C19007T Polymorphism of <i>ERCC1</i> and Its Correlation with the Risk of Epithelial Ovarian and Endometrial Cancer in Korean Women. <i>Gynecologic and Obstetric Investigation</i> , 2007, 64, 84-88.	1.6	15
96	Interleukin-1 Beta -511 Polymorphism and Risk of Cervical Cancer. <i>Journal of Korean Medical Science</i> , 2007, 22, 110.	2.5	31
97	Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix. <i>Cancer Letters</i> , 2006, 237, 305-311.	7.2	16
98	Comparison of DNA hypermethylation patterns in different types of uterine cancer: Cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. <i>International Journal of Cancer</i> , 2006, 118, 2168-2171.	5.1	90
99	Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. <i>Experimental and Molecular Medicine</i> , 2006, 38, 320-324.	7.7	78
100	Cyclooxygenase expressions and response to radiation therapy in uterine cervix cancer. <i>Korean Journal of Gynecologic Oncology</i> , 2006, 17, 105.	0.1	1
101	Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. <i>Gynecologic Oncology</i> , 2005, 96, 173-180.	1.4	99
102	Feasibility of Radical Surgery in the Management of Elderly Patients with Uterine Cervical Cancer in Korea. <i>Gynecologic and Obstetric Investigation</i> , 2005, 59, 165-170.	1.6	12
103	Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical cancer in Korean women. <i>Cancer Letters</i> , 2005, 217, 191-196.	7.2	15
104	Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 92, 927-935.	1.4	58
105	p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer1. <i>Gynecologic Oncology</i> , 2004, 93, 499-505.	1.4	60
106	Multiple HPV infection in cervical cancer screened by HPVDNAChipâ„¢. <i>Cancer Letters</i> , 2003, 198, 187-192.	7.2	70
107	Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. <i>Cancer Letters</i> , 2002, 184, 57-63.	7.2	75
108	Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 184, 55-58.	1.3	40

#	ARTICLE	IF	CITATIONS
109	The Role of the Hinge Region of the Luteinizing Hormone Receptor in Hormone Interaction and Signal Generation. <i>Journal of Biological Chemistry</i> , 2001, 276, 3451-3458.	3.4	47
110	Hormone Interactions to Leu-rich Repeats in the Gonadotropin Receptors. <i>Journal of Biological Chemistry</i> , 2001, 276, 3443-3450.	3.4	18
111	Hormone Interactions to Leu-rich Repeats in the Gonadotropin Receptors. <i>Journal of Biological Chemistry</i> , 2001, 276, 3426-3435.	3.4	49
112	Hormone Interactions to Leu-rich Repeats in the Gonadotropin Receptors. <i>Journal of Biological Chemistry</i> , 2001, 276, 3436-3442.	3.4	39
113	Eight Cases of Synchronous Primary Carcinomas of The Endometrium and The Ovary. <i>Korean Journal of Gynecologic Oncology and Colposcopy</i> , 2001, 12, 203.	0.0	0
114	Treatment Efficacy of High-Dose Megestrol Acetate (Megace) in Young Women with Early Stage of Endometrial Carcinoma. <i>Korean Journal of Gynecologic Oncology and Colposcopy</i> , 1998, 9, 300.	0.0	0
115	Risk Factors Associated with Uterine Cervical Cancer in Korea: A Case-Control Study with Special Reference to Sexual Behavior. <i>Journal of Epidemiology</i> , 1997, 7, 117-123.	2.4	26